Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

Fig. 1

Reduction in FES uptake after elacestrant treatment in a patient with ESR1 mutation. Images depict FES-PET scan in the patient at baseline (left) and 14 days after receiving elacestrant 400 mg daily (right), at which time a 96.6% reduction in FES uptake was observed. Physiologic FES uptake/excretion is observed in the liver, intestines, bladder, and port-a-cath infusion line; pathologic uptake is observed in bone lesions and lymph nodes

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us